Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: The treatment strategy for hepatitis C virus (HCV) has been changing rapidly since the introduction of direct-acting antivirals such as daclatasvir (DCV) and asunaprevir (ASV). We evaluated the efficacy and safety of DCV and ASV for HCV in real-life practice. Methods: Patients were treated with 60 mg of DCV once daily plus 200 mg of ASV twice daily for 24 weeks, and followed for 12 weeks. The primary endpoint was a sustained virological response at 12 weeks after treatment (SVR12) and safety. Results: This retrospective study included eight patients with chronic HCV genotype 1b infection. All of the enrolled patients were diagnosed with liver cirrhosis, and their mean age was 65.75 years. One patient was a nonresponder and two patients relapsed with previous pegylated interferon (PegIFN) and ribavirin (RBV) treatment. None of the patient showed NS5A mutation. An SVR12 was achieved in 88% of cases by the DCV and ASV combination therapy. The serum transaminase level and the aspartate-aminotransferase-to-platelet ratio were improved after the treatment. DCV and ASV were well tolerated in most of the patients, with treatment discontinuation due to adverse events (elevated liver enzyme and decompensation) occurring in two patients. Conclusions: In this study, combination of DCV and ASV treatment achieved a high sustained virological response with few adverse events even in those with cirrhosis, advanced age, and nonresponse/relapse to previous interferon-based therapy. Close monitoring of safety issues may be necessary when treating chronic HCV patients receiving DCV and ASV, especially in older patient and those with cirrhosis.
Abstract
Background/Aims: The treatment strategy for hepatitis C virus (HCV) has been changing rapidly since the introduction of direct-acting antivirals such as daclatasvir (DCV) and asunaprevir (ASV). We evaluated the efficacy and safety of DCV and ASV for HCV in real-life practice. Methods: Patients were treated with 60 mg of DCV once daily plus 200 mg of ASV twice daily for 24 weeks, and followed for 12 weeks. The primary endpoint was a sustained virological response at 12 weeks after treatment (SVR12) and safety. Results: This retrospective study included eight patients with chronic HCV genotype 1b infection. All of the enrolled patients were diagnosed with liver cirrhosis, and their mean age was 65.75 years. One patient was a nonresponder and two patients relapsed with previous pegylated interferon (PegIFN) and ribavirin (RBV) treatment. None of the patient showed NS5A mutation. An SVR12 was achieved in 88% of cases by the DCV and ASV combination therapy. The serum transaminase level and the aspartate-aminotransferase-to-platelet ratio were improved after the treatment. DCV and ASV were well tolerated in most of the patients, with treatment discontinuation due to adverse events (elevated liver enzyme and decompensation) occurring in two patients. Conclusions: In this study, combination of DCV and ASV treatment achieved a high sustained virological response with few adverse events even in those with cirrhosis, advanced age, and nonresponse/relapse to previous interferon-based therapy. Close monitoring of safety issues may be necessary when treating chronic HCV patients receiving DCV and ASV, especially in older patient and those with cirrhosis.
참고문헌 (33)
- World Health Organization, "WHO fact sheet 164-hepatitis C", ~ (2014)
- Kim AI, "Treatment of hepatitis C", Am J Med, 118, pp.808~815 (2005)
- Ghany MG, "Diagnosis, management, and treatment of hepatitis C: an update", Hepatology, 49, pp.1335~1374 (2009)
- Gower E, "Global epidemiology and genotype distribution of the hepatitis C virus infection", J Hepatol, 61(1 Suppl), pp.S45~S57 (2014)
- European Association for the Study of the Liver, "EASL Clinical Practice Guidelines: Management of hepatitis C virus infection", J Hepatol, 55, pp.245~264 (2011)
- Melia MT, "Racial differences in hepatitis C treatment eligibility", Hepatology, 54, pp.70~78 (2011)
- Di Bisceglie AM., "Natural history of hepatitis C: its impact on clinical management", Hepatology, 31, pp.1014~1018 (2000)
- "Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus", Hepatology, 62, pp.932~954 (2015)
- "EASL Recommendations on Treatment of Hepatitis C 2015", J Hepatol, 63, pp.199~236 (2015)
- Gao M., "Antiviral activity and resistance of HCV NS5A replication complex inhibitors", Curr Opin Virol, 3, pp.514~520 (2013)
- McPhee F, "Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)", Antimicrob Agents Chemother, 56, pp.5387~5396 (2012)
- Lok AS, "Randomized trial of daclatasvir and asunaprevir with or without PegIFN", RBV for hepatitis C virus genotype 1 null responders, 2014, pp.60, 490~499
- Chayama K, "Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders", Hepatology, 55, pp.742~748 (2012)
- Kumada H, "Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection", Hepatology, 59, pp.2083~2091 (2014)
- Manns M, "All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study", Lancet, 384, pp.1597~1605 (2014)
- Muir AJ, "Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis", JAMA, 313, pp.1736~1744 (2015)
- Everson GT, "Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatmentnaive patients with HCV genotype 1 infection", Gastroenterology, 146, pp.420~429 (2014)
- The Asia-Pacific perspective: redefining obesity and its treatment: Health Communications Australia, "Bassett J", Organization WH, ~ (2000)
- Wai CT, "A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C", Hepatology, 38, pp.518~526 (2003)
- Seong MH, "Clinical and epidemiological features of hepatitis C virus infection in South Korea: a prospective, multicenter cohort study", J Med Virol, 85, pp.1724~1733 (2013)
- Lee MH, "Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma", Int J Cancer, 135, pp.1119~1126 (2014)
- Zeuzem S, "Telaprevir for retreatment of HCV infection", N Engl J Med, 364, pp.2417~2428 (2011)
- Poynard T, "Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa", Ribavirin Therapy, 2009, pp.136, 1618~1628.e2
- Shiffman ML, "Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment", Gastroenterology, 126, pp.1015~1023 (2004)
- Akhtar E, "Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis", Liver Int, 35, pp.30~36 (2015)
- Bacon BR, "Boceprevir for previously treated chronic HCV genotype 1 infection", N Engl J Med, 364, pp.1207~1217 (2011)
- Poordad F, "Boceprevir for untreated chronic HCV genotype 1 infection", N Engl J Med, 364, pp.1195~1206 (2011)
- Jacobson IM, "Telaprevir for previously untreated chronic hepatitis C virus infection", N Engl J Med, 364, pp.2405~2416 (2011)
- Hézode C, "Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890", J Hepatol, 59, pp.434~441 (2013)
- Bruno S, "Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis", Hepatology, 51, pp.388~397 (2010)
- Bourlière M, "Future treatment of patients with HCV cirrhosis", Liver Int, 32(Suppl 1), pp.113~119 (2012)
- McPhee F, "High sustained virologic response to daclatasvir plus asunaprevir in elderly and cirrhotic patients with hepatitis C virus genotype 1b without baseline NS5A polymorphisms", Adv Ther, 32, pp.637~649 (2015)
- Suzuki F, "Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b", J Clin Virol, 54, pp.352~354 (2012)